# Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)

> **NCT00429923** · PHASE3 · COMPLETED · sponsor: **Sirion Therapeutics, Inc.** · enrollment: 219 (actual)

## Conditions studied

- Inflammation

## Interventions

- **DRUG:** Difluprednate
- **DRUG:** Difluprednate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00429923
- **Lead sponsor:** Sirion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2009-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00429923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00429923, "Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00429923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*